Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 1.4 years of cash runway.
CTNM Financials Contineum Therapeutics, Inc.
3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$60M | — | — | -23.0% | -21.7% | -$56M | — | $76M |
| 2024 | $0 | -$42M | — | — | -21.3% | -19.9% | -$33M | — | $22M |
| 2023 | $50M | $23M | 0.0% | 32.2% | -33.4% | 17.4% | $19M | — | $16M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$15M | — | — | -6.3% | -6.1% | -$12M | — | $15M |
| Mar '26 | — | -$14M | — | — | -5.8% | -5.5% | -$17M | — | $20M |
| Dec '25 | — | -$15M | — | — | -5.8% | -5.5% | -$13M | — | $76M |
| Sep '25 | — | -$13M | — | — | -7.1% | -6.7% | -$12M | — | $43M |
| Jun '25 | — | -$16M | — | — | -9.4% | -8.8% | -$16M | — | $21M |
| Mar '25 | — | -$16M | — | — | -8.7% | -8.1% | -$14M | — | $22M |
| Dec '24 | $0 | -$15M | — | — | -7.4% | -6.8% | -$10M | — | $22M |
| Sep '24 | $0 | -$10M | — | — | -4.9% | -4.8% | -$6M | — | $41M |
| Jun '24 | $0 | -$9M | — | — | -4.1% | -4.1% | -$9M | — | $77M |
| Mar '24 | — | -$8M | — | — | 11.1% | -6.8% | -$8M | — | $16M |
| Dec '23 | $0 | -$8M | — | — | 11.4% | -6.0% | -$11M | — | $16M |
| Sep '23 | $0 | -$6M | — | — | 10.2% | — | -$5M | — | — |
| Jun '23 | $50M | $42M | 0.0% | 77.9% | -75.0% | — | $41M | — | — |
| Mar '23 | — | -$5M | — | — | 4.9% | — | -$5M | — | — |
Valuation over time
How the market has priced CTNM against its own fundamentals since 2024-04 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 26.0× (Apr '24) to 24.5× (Nov '24).
- The price-to-sales ratio has fallen from 11.8× (Apr '24) to 11.1× (Nov '24).
P/E
P/S
Frequently asked questions
Is CTNM growing its revenue and profit?
See the revenue and net-income charts above for Contineum Therapeutics, Inc.'s multi-year trend.
How much debt does CTNM have?
As of FY2025, Contineum Therapeutics, Inc. reported — of total debt against $76M of cash.
What is CTNM's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is CTNM's P/E ratio?
As of Sep '26, Contineum Therapeutics, Inc. traded at a price-to-earnings ratio of about 24.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.